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Abstract
Introduction Genetic polymorphisms in the promoter region of
the tumour necrosis factor (TNF) gene can regulate gene
expression and have been associated with inflammatory and
malignant conditions. We have investigated two polymorphisms
in the promoter of the TNF gene (-308 G>A and -238 G>A) for
their role in breast cancer susceptibility and severity by means
of an allelic association study.
Methods Using a case–control study design, breast cancer
patients (n = 709) and appropriate age-matched and sex-
matched controls obtained from the Breast Screening Unit (n =
498) were genotyped for these TNF polymorphisms, using a
high-throughput allelic discrimination method.
Results Allele frequencies for both polymorphisms were similar
in both breast cancer cases and controls. However, the -308
polymorphism was found to be associated with vascular
invasion in breast tumours (P = 0.024). Comparison with other
standard prognostic indices did not show any association for
either genotype.
Conclusions We demonstrated no association between the -
308G>A polymorphism and the -238G>A polymorphism in the
promoter region of TNF and susceptibility to breast cancer, in a
large North European population. However, the -308 G>A
polymorphism was found to be associated with the presence of
vascular invasion in breast tumours.
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Introduction
The role of genetic factors in the epidemiology and patho-
genesis of both sporadic breast cancer and familial breast
cancer are now well established [1,2]. Only a small minority
(~5%) of patients with breast cancer develop the disease
as a result of inheritance of germline mutations in dominant,
highly penetrant susceptibility genes such as BRCA1 and
BRCA2. However, polymorphisms in genes involved in the
complex mechanisms of carcinogenesis may confer low
penetrant susceptibility to breast cancer in a significant
proportion of the remainder of the patients [2-4].
The multifunctional cytokine, tumour necrosis factor (TNF),
is involved in the promotion of inflammatory responses and
plays a critical role in the pathogenesis of inflammatory,
autoimmune and malignant diseases [5]. Initially proposed
to have anti-carcinogenic effects [6,7], TNF was later
shown to be tumourigenic in both in vitro studies [8] and in
vivo studies [9-11]. High plasma TNF levels in cancer
patients are associated with a poor disease outcome
[12,13]. TNF is also a key angiogenic molecule that may
promote angiogenesis directly by stimulating endothelial
cell proliferation and indirectly by modulating expression of
other proangiogenic factors [14]. Moreover, TNF is known
to induce expression of adhesion molecules thought to be
involved in the increased motility and invasive/metastatic
behaviour of tumour cells [15].
Single nucleotide polymorphisms at -308 and -238 of the
promoter region of the TNF gene have been commonly
studied [16]. The -308 polymorphism is a G → A substitu-
tion and reportedly affects gene expression, the rare AR395FAM = 6-carboxy-fluorescein; PCR = polymerase chain reaction; TET = 6-carboxy-4,7,2',7'-tetrachlorofluorescein; TNF = tumour necrosis factor.
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This influence on gene transcription is also supported by
gene reporter assays [19]. For the -238 polymorphism, the
common G allele has been shown to be associated with
high TNF production [20].
Studies in Tunisian populations have suggested that the -
308 polymorphism may be associated with breast cancer
[21,22]. However, there are conflicting data from a Korean
study [23]. The -238 polymorphism has previously been
found to have an apparently protective role against a range
of tumours [24]. The aim of the current study, therefore,
was to investigate the role of these two polymorphisms (-
308 G>A and -238 G>A) in breast cancer susceptibility
and severity, in a large Northern European population.
Methods
Patients and controls
Seven hundred and nine pathologically confirmed breast
cancer patients were recruited from outpatient clinics at the
Royal Hallamshire Hospital, Sheffield, UK. Four hundred
and ninety-eight controls were recruited from women
attending the Sheffield Breast Screening Service. The
study was restricted to white Caucasians, as there were
insufficient individuals from other ethnic groups for mean-
ingful analysis. The South Sheffield Research Ethics Com-
mittee approved the study (reference number SS98/137),
and informed written consent was obtained from all
participants.
DNA extraction and genotyping
Genomic DNA was extracted from EDTA-preserved
peripheral venous blood from all individuals, as described
previously [25]. Genotyping of the polymorphisms was per-
formed by the 5' nuclease PCR method, using the ABI/PE
Biosystems Taqman™ system (PE Biosystems, Foster City,
CA, USA), essentially as described by di Giovine and col-
leagues [25]. Using specific primer and probe sequences
(Table 1), PCR amplification was carried out separately for
the two polymorphisms. The final volume for PCR was 25
µl.
The final concentrations of the constituents for the TNF -
308 polymorphism were 0.8 ng/µl genomic DNA template,
300 nM each primer, 50 nM 6-carboxy-fluorescein (FAM)-
labelled probe, 125 nM 6-carboxy-4,7,2',7'-tetrachlorofluo-
rescein (TET)-labelled probe and 1 × (12.5 µl) Universal
PCR mastermix (PE Biosystems) containing optimised
buffer components and Rox reference dye. The final con-
centrations of the constituents for the TNF -238 polymor-
phism were 0.8 ng/µl genomic DNA template, 900 nM
each primer, 50 nM FAM-labelled probe, 75 nM TET-
labelled probe and 1 × (12.5 µl) Universal PCR mastermix.
The PCR amplification cycles (for both polymorphisms)
were 50°C for 2 min and 95°C for 10 min, followed by 40
cycles of 95°C for 15 s and 58°C for 1 min. Levels of FAM
and TET fluorescence were determined, and the allelic dis-
crimination was carried out using the ABI 7200 Sequence
Detector (PE Biosystems).
Quality control of genotyping data was verified by repeat
testing of 15% of randomly selected individuals for each of
the polymorphisms tested (12 samples from each batch of
72). There were no discrepancies encountered on these
analyses.
Statistical methods
All data were entered into a Microsoft Access database
and exported to SPSS (version 10.0 for Windows; SPSS
UK Ltd., Surrey, UK) for statistical analyses. Genotype data
were available for 708 breast cancer cases (705 cases and
708 cases for the -308 and the -238 genotypes, respec-
tively) and for 498 breast screening controls (498 controls
and 495 controls for the -308 and the -238 genotypes,
respectively). Odds ratios and 95% confidence intervals
were determined for the genotype comparisons.
The age at diagnosis/recruitment was compared between
cases and controls using the two-sample Mann–Whitney U
test. A family history of breast cancer (defined as the
presence of at least one first-degree or second-degree rel-
ative with breast cancer) was compared between cases
Table 1
Primer and probe sequences for the two polymorphisms
Tumour necrosis factor (-308) Tumour necrosis factor (-238)
Forward primer 5'-GGC CAC TGA CTG ATT TGT GTG T-3' 5'-GCA TCA AGG ATA CCC CTC ACA-3'
Reverse primer 5'-CAA AAG AAA TGG AGG CAA TAG GTT-3' 5'-ATC AGT CAG TGG CCC AGA AGA-3'
Probe FAM FAM AAC CCC GTC CTC ATG CCC C TAMRA FAM TCC TCC CTG CTC TGA TTC CGA TAMRA
Probe TET TET ACC CCG TCC CCA TGC CC TAMRA TET CCT CCC TGC TCC GAT TCC G TAMRA
FAM, 6-carboxy-fluorescein; TET, 6-carboxy-4,7,2',7'-tetrachlorofluorescein.
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otypes relative to pathological prognostic indicators was
performed using the chi-square test and Fisher's exact test
(for smaller numbers on subgroup analysis). All tests were
two sided.
Results
There were no significant differences between the breast
cancer cases and the mammography screening controls for
age at diagnosis/recruitment, with a median age of 57
years for both groups (P = 0.637). However, the age range
of the controls was narrower (45–77 years for controls ver-
sus 28–88 years for cases) since the majority of controls
were within the age range of women routinely invited for
screening (50–64 years). Breast cancer patients, as
expected, were more likely to have a positive family history
(32% versus 22.3%, respectively; P < 0.001).
The genotype frequencies of the two polymorphisms are
presented in Table 2. The genotype frequencies of the -308
and -238 polymorphisms in the control population are in
Hardy–Weinberg equilibrium (P = 0.758 and P = 1.0,
respectively).
There was no association between either the -308 polymor-
phism (odds ratio [95% confidence interval] = 0.82 [0.64–
1.04]) or the -238 polymorphism (odds ratio [95% confi-
dence interval] = 1 [0.70–1.41]) and breast cancer. Also,
the rare alleles of the two polymorphisms were not associ-
ated with breast cancer in subgroups of individuals with a
family history of breast cancer (odds ratio for -308 polymor-
phism [95% confidence interval] = 0.79 [0.49–1.26]; odds
ratio for -238 polymorphism [95% confidence intervals] =
1.06 [0.53–2.14]).
Table 3 presents the distribution of genotypes for both the
-308 and the -238 polymorphisms in breast cancer patients
with different histological features indicative of prognosis.
A significant association between the TNF -308AA geno-
type and vascular invasion was observed (Table 3). Com-
parison of TNF -308AA versus TNF -308GG for the
presence of vascular invasion yielded an odds ratio of 1.69
(95% confidence interval = 1.07–2.7) and the chi-squared
test for the trend was significant (P = 0.023), indicating a
dose effect for carriage of the rare (A) allele. Analysis of all
other subgroups as presented in Table 3 using allele car-
riage rates demonstrated similar results to those obtained
with individual genotype frequencies (data not shown).
Discussion
We studied a large cohort of 709 breast cancer patients
and 498 unrelated controls to assess the role of TNF poly-
morphisms in breast cancer. We sought to ensure that this
study had sufficient power to identify any clinically relevant
genotype–phenotype associations. We found no evidence
of association between the two polymorphisms in the TNF
promoter region and breast cancer susceptibility. This is in
contrast to a previous study in a Tunisian population that
demonstrated a positive association between the -308 pol-
ymorphism and breast cancer susceptibility with a signifi-
cant relative risk of 3.2 [21]. The same investigators
subsequently confirmed this observation in a larger cohort
of breast cancer patients (n = 243) and controls (n = 174),
as well as showing a relationship with clinical outcome
[22]. A study of the -308 polymorphism in a Korean popu-
lation comprising 95 breast cancer cases and 190 con-
trols, however, showed no such association [23].
The current study has a greater power than any of the pre-
ceding studies to detect small associations between these
polymorphisms and breast cancer: a power of 93% to
detect an odds ratio of 1.5 (with a type I error of 0.05) for
the -308G>A polymorphism. In addition, previous studies
did not ensure age matching and sex matching between
cases and controls. However, inherent differences
between populations may account for the conflicting
results obtained in studies of the predisposition of the TNF
genotype to cancer. Conventional case–control gene asso-
ciation studies have been known to produce false-positive
results partly because of population stratification as well as
poor study design [26].
Our control cohort, identified from a breast screening pop-
ulation, is sex matched and ethnicity matched to the cases.
This is a population in which the disease under investiga-
tion typically occurs, and thus this control group may be
Table 2
Genotype frequencies of the two tumour necrosis factor (TNF) polymorphisms in breast cancer patients and controls
Genotype TNF-α-308G>A polymorphism TNF-α-238G>A polymorphism
Breast cancer (n = 705) Screening controls (n = 498) Breast cancer (n = 708) Screening controls (n = 495)
GG 475 (67.4%) 313 (62.9%) 621 (87.7%) 434 (87.7%)
GA 208 (29.5%) 167 (33.5%) 84 (11.9%) 59 (11.9%)
AA 22 (3.1%) 18 (3.6%) 3 (0.4%) 2 (0.4%)
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otype frequencies of the polymorphisms were also com-
pared with well-established tumour severity indices
(tumour grade, nodal status and vascular invasion). An
association was demonstrated between the TNF -308 pol-
ymorphism and the presence of vascular invasion in
tumours. This observation suggests that carriage of -308A
may predispose to more aggressive disease, possibly as a
result of increased levels of TNF protein.
A positive association found on subgroup analysis, as in
this case, should be regarded with caution, as the likeli-
hood of finding a positive result by chance is higher. Cor-
recting for multiple testing is commonly undertaken for
subgroup analyses (e.g. Bonferroni correction). Such sta-
tistical tests are inappropriate when the variables under
investigation are highly correlated, however, as is the case
with the prognostic indicators for breast cancer [27]. It is
also interesting to note that the genotype distributions
across all the remaining histological variants were remarka-
bly consistent (Table 3). Furthermore, there is a biological
plausibility to this observation, in view of the role played by
TNF in the promotion of tumour angiogenesis, which is a
requirement for tumour proliferation [28].
Although the exact mechanisms underlying vascular inva-
sion remain unexplained, a positive correlation has been
demonstrated between blood vessel density and vascular
invasion in tumours [29]. The hypothesis that TNF,
produced in the tumour microenvironment, may promote
cancer development and dissemination is supported by evi-
dence from a range of animal experiments [30]. Ovarian
cancer xenografts treated with TNF showed evidence of
increased peritoneal adhesion and solid tumour formation
[31], and overexpression of TNF confers metastatic proper-
ties on transplantable tumours in nude mice [32-34].
Although many genetic polymorphisms have been studied
for their association with breast cancer, only a few have
been shown to be consistently associated with increased
breast cancer risk [2,4]. Further studies are required to
establish the significance of the positive association
Table 3
Genotype frequencies of tumour necrosis factor (TNF) polymorphisms in relation to pathological indices of breast cancer severity
Pathological feature Number of patients (%) P value
GG GA AA
TNF -238 polymorphism
Nodal status
Negative 387 (88.8) 46 (10.6) 3 (0.7)
Positive 171 (85.5) 29 (14.5) 0 (0) 0.20a
Grade
Grade 1/2 363 (88.1) 47 (11.4) 2 (0.5)
Grade 3 189 (87.1) 27 (12.4) 1 (0.5) 0.87a
Vascular invasion
Negative 417 (88.3) 53 (11.2) 2 (0.4)
Positive 105 (89.0) 13 (11.0) 0 (0) 1.0a
TNF -308 polymorphism
Nodal status
Negative 299 (68.9) 123 (28.3) 12 (2.8)
Positive 129 (64.8) 62 (31.2) 8 (4.0) 0.50b
Grade
Grade 1/2 286 (69.6) 112 (27.3) 13 (3.2)
Grade 3 140 (65.1) 68 (31.6) 7 (3.3) 0.50b
Vascular invasion
Negative 326 (69.2) 132 (28.0) 13 (2.8)
Positive 70 (60.3) 38 (32.8) 8 (6.9) 0.044b
a Fisher's exact test. b Chi-square test.
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including the study of other polymorphisms in angiogenic
genes, which are thought to be important in solid cancers
[35].
We recently investigated the role of polymorphisms in key
angiogenic genes including vascular endothelial growth
factor and endostatin, and we found an association
between an endostatin polymorphism and invasiveness in
breast cancer [36]. As further polymorphisms are being
detected and investigated in several different classes of
genes, including those involved in carcinogen and steroid
metabolism, in angiogenesis, in DNA repair and in apopto-
sis, the search for low penetrance genes that may influence
breast cancer susceptibility and severity in the general pop-
ulation continues.
Conclusions
We have not demonstrated an association between TNF
polymorphisms at positions -238 and -308 and breast can-
cer. However, an association was found between the rare
allele at position -308 and the presence of vascular inva-
sion in breast tumours. This finding suggests a possible
role for the TNF protein in the process of vascular invasion,
and studies of the functional consequences of variations
within the TNF gene in breast cancer patients are
warranted.
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